tbuckley/cabot-search huggingface dataset:
AB0658 Cross-Cultural Adaptation, Reliability, and Validity of the Turkish Version of the Compliance Questionnaire on Rheumatology (CQR-T) in Patients with Behçet's Disease
Authors: F.I. Cinar, M. Cinar, S. Yilmaz, C. Acikel, H. Erdem, S. Pay, I. Simsek
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Compliance to treatment can be defined as the degree to which patient behavior is consistent with the recommendations made by healthcare providers. Determining the level of the patient9s compliance will improve the management of a certain disease. Currently, the only self-reported questionnaire for assessing the compliance of patients with rheumatic disease is the 19-item Compliance Questionnaire on Rheumatology (CQR). <h3>Objectives</h3> The aim of this study was to examine the psychometric properties of the Turkish version of the Compliance Questionnaire on Rheumatology (CQR-T) for patients with Behçet9s disease (BD) <h3>Methods</h3> A sample of 105 Turkish patients with BD participated in this study. The scale was cross-culturally adapted through a process including translation, comparison with versions in other languages, back translation, and pretesting. Construct validity was evaluated by factor analysis, and criterion validity was evaluated using the Morisky Medication Adherence Scale (MMAS). <h3>Results</h3> The mean age of the study group was 30.87±8.06 years. The majority of the participants was male (89.5%). Mean disease duration was 5.67±4.68 years.Among the current medical treatment agents, colchicine and azathioprine were the most commonly used (79 and 50 patients, respectively). The CQR-T demonstrated acceptable internal consistency (Cronbach9s alpha coefficient = 0.832), adequate test–retest reliability (intraclass correlation coefficient = 0.630), and correlations with MMAS scores (r=−0.389; p&lt;0.001), indicating convergent validity. <h3>Conclusions</h3> The CQR-T was found to be a valid and reliable instrument for evaluating the compliance of Turkish BD patients with prescribed medications. The CQR-T might be a helpful tool in two ways: for determining the level of compliance of patients with BD and for adjusting their management and follow-up based on the results. <h3>References</h3> de Klerk, E., van der Heijde, D., Landewé, R., van der Tempel, H., &amp; van der Linden, S. (2003). The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. The Journal of Rheumatology, 30, 2469-2475. de Klerk, E., van der Heijde, D., van der Tempel, H., &amp; van der Linden, S. (1999). Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. The Journal of Rheumatology, 26, 2635–2641. Fialko, L., Garety, P.A., Kuipers, E., Dunn, G., Bebbington, P.E., Fowler, D., &amp; Freeman, D. (2008). A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophrenia Research,100, 53-59. <h3>Disclosure of Interest</h3> None declared
Focally Increased MIBG Activity in the Muscle
Authors: Xia Bai, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2015)

A 6-month-old female infant with known left adrenal neuroblastoma and liver metastasis underwent MIBG scan. The images not only revealed elevated activity in the abdomen, but also showed multiple foci of increased activity in the muscles of bilateral upper thighs, which corresponded to the injection sites of LOVENOX.
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Authors: F. Trillsch, S. Mahner, F. Hilpert, L. Davies, E. García-Martínez, G. Kristensen, A. Savarese, P. Vuylsteke, M. Los, F. Zagouri, L. Gladieff, J. Sehouli, C. Khoon Lee, V. Gebski, E. Pujade-Lauraine
Journal: Annals of Oncology (2016)
Elliptopoikilocytosis associated with the alpha 469 His--&gt;Pro mutation in spectrin Barcelona (alpha I/50-46b)
Authors: N Dalla Venezia, N Alloisio, A Forissier, L Denoroy, M Aymerich, JL Vives- Corrons, J Besalduch, I Besson, J Delaunay
Journal: Blood (1993)
Respiratory Distress Syndrome in Second-Born versus First-Born Twins
Authors: C Arnold, F H McLean, M S Kramer, R H Usher
Journal: New England Journal of Medicine (1987)

The well-known increased risk of the respiratory distress syndrome in a twin born second as compared with the twin born first is usually attributed to the second twin's predisposition to depression at birth ("asphyxia"). We analyzed the etiologic roles of birth order, presentation, and depression at birth in the development of the respiratory distress syndrome in matched case-control populations drawn from 221 preterm twin pairs. Among the 39 twin pairs discordant for respiratory distress syndrome, the second twin was the affected member in 31 pairs. Second birth order was the only independent risk factor, but only in vaginal deliveries (matched odds ratio, 14.2; 95 percent confidence interval, 2.5 to 81.1). Second twins delivered abdominally did not have an increased risk relative to first twins (odds ratio, 0.9; confidence interval, 0 to 17.8). When depression at birth was evaluated as an outcome variable, malpresentation, rather than birth order, was the major risk factor (independent matched odds ratios of 2.7 [confidence interval, 1.0 to 7.5] and 1.3 [0.7 to 2.5], respectively). Thus, second twins' increased risk of respiratory distress syndrome cannot be explained by a predisposition to depression at birth; a more important factor may be that second twins do not benefit from the salutary effects of labor to the same extent as first twins.
AB1154 Obesity is a Risk Factor for Depression in Women with Systemic Lupus Erythematosus (SLE) and WMEN with Rheumatoid Arthritis (RA):
Authors: P. Katz, S. Pedro, K. Michaud
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> General population studies have found significant relationships between obesity and depression, including identifying obesity as a risk factor for onset of depression. In SLE and RA, rates of depression are elevated, but the role of obesity as an independent risk factor for depression in these conditions has not been studied. <h3>Objectives</h3> To examine the risk of depression onset for obese and non-obese women with SLE or RA. <h3>Methods</h3> Analyses use data from the National Data Bank for Rheumatic Diseases, collected at 6-month intervals primarily by questionnaire. All participants have physician confirmed SLE/RA. Depression was determined through self-report. Body mass index (BMI) was calculated from self-reported height and weight; obesity was defined using validated SLE- and RA-specific BMI cut-points (SLE ≥26.8; RA ≥26.1)<sup>1,2</sup>. Cox proportional hazard models estimated the risk of becoming depressed associated with obesity at baseline. Multivariate analyses adjusted for age, race, current smoking, prednisone use, baseline disease activity (SLE: 0-100 rating of SLE activity; RA: Rheumatoid Arthritis Disease Activity Index [RADAI]), baseline functioning (SF-36 Physical Component Score), and changes in disease activity and functioning between baseline and the interview prior to depression onset (or last observation). Women who reported current or past depression at baseline were excluded from analysis. <h3>Results</h3> For SLE, 827 women were included; for RA, 12,844 women. Mean follow-up time was 2.7 years for SLE and 3.7 years for RA. Using disease-specific obesity criteria, 52.0% of women with SLE and 44.5% of women with RA were obese at baseline. Among women with SLE, 24.3% who were obese later developed depression, compared to 18.3% of those not obese (unadjusted hazard ratio [HR]=1.43 [1.06,1.93]). Adjusting for covariates, obesity remained a significant independent risk factor for development of depression (HR =2.82 [1.40, 5.68]). Among women with RA, 20.2% of those who were obese later developed depression, compared to 16.7% of those not depressed (HR=1.28, 95% CI 1.18,1.38). Adjusting for covariates, obesity remained a significant independent risk factor for development of depression (HR=1.14 [1.03,1.27]). <h3>Conclusions</h3> Obesity appears to be an independent risk factor for development of depression among women with SLE and RA, even after controlling for disease activity, function, changes in disease activity and function, and other relevant factors. This is a clinically important finding, as obesity is modifiable, and reducing obesity is likely to lead to additional health benefits such as reduced cardiovascular disease. <h3>References</h3> Katz et al. Arthritis Care Res 2011; 63:261. Katz et al. Arthritis Care Res 2013;65:62. <h3>Disclosure of Interest</h3> None declared
Giant Fibrovascular Polyp of the Esophagus
Authors: B.  M.  Devereaux, J.  K.  LeBlanc, K.  Kesler, J.  Brooks, G.  A.  Lehman, S.  Sherman, D.  Ciaccia
Journal: Endoscopy (2003)

The role of endoscopic ultrasound (EUS) in the diagnosis and management of a giant fibrovascular polyp of the esophagus in a 46-year-old woman is described here. The fibrovascular polyp was detected at esophagogastroduodenoscopy, and EUS demonstrated that it originated from the submucosa. EUS-guided fine-needle aspiration was performed, and cytological examination of the specimen revealed benign fibro-fatty elements. The lesion was resected via a transcervical esophagotomy. The literature on fibrovascular polyps is reviewed.
AB1184 Prevalence of Low Back Pain and Chronic Low Back Pain and Related Factors: Outcomes of Cappadocia Chronic Diseases Epidemiological Study: Table 1.
Authors: U. Kalyoncu, A. Akdogan, O. Karadag, A. Erden, L. Kilic, S.A. Bilgen, S. Kiraz, I. Ertenli
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Low back pain (LBP) and chronic LBP are one of the most frequent medical conditions in the population. <h3>Objectives</h3> The present population-based epidemiological study aimed to determine the frequency of LBP and CLBP and associated factors. <h3>Methods</h3> In 2013, a cohort for chronic diseases was initiated by the Turkish Society of Internal Medicine. CLBP was defined as a LBP lasting for longer than3 months. Demographic characteristics and habits of the participants, self-reported joint swelling, and presence of recurrent aphthous stomatitis were questioned. <h3>Results</h3> Data of 11,049 participants (mean age, 44.6±16.4 years; 56.1% males) were evaluated. Of the participants, 44.3% had LBP, 22.7% had CLBP, 19.8% had self-reported joint swelling, and 13.2% had oral aphthous lesions. In multivariate analysis, CLBP was positively associated with female gender, advanced age, low education level, oral aphthous lesion, self-reported joint swelling, smoking, and high body mass index, whereas a negative correlation was determined with alcohol consumption (Table 1). <h3>Conclusions</h3> In the present study, the frequency of LBP and CLBP were about 44% and 23%, respectively. In addition to previously reported classical risk factors, recurrent aphthous lesions were associated with both LBP and CLBP. <h3>Financial Interests</h3> The present study was unconditionally funded by the Turkish Society of Internal Medicine, which provided financial support for data collection and analysis and manuscript preparation. The Turkish Society of Internal Medicine had no contribution to the study design and interpretation of the results. The authors declare no conflict of interests. <h3>Disclosure of Interest</h3> None declared
The clinical cancer researcher--still an embattled species.
Authors: E Frei, E J Freireich
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.9.1639 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8355033 The clinical cancer researcher--still an embattled species. E Frei 3rdxE Frei 3rdSearch for articles by this author , E J FreireichxE J FreireichSearch for articles by this author Show More Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115. https://doi.org/10.1200/JCO.1993.11.9.1639 First Page PDF © 1993 by American Society of Clinical Oncology
Soundings: Dear diary
Authors: Colin Douglas
Journal: BMJ (2004)

Here in Auchendreich our response to the challenge of change combines in judicious measure both the positive and the practical; and we find that open discussion allows us to test arguments and conclusions, thus ensuring that well managed change brings maximum benefit throughout our newly created unitary healthcare system, NHS Auchendreich.

So it was that, late in the evening of last week's Burns supper in the Dreichmuir Station Hotel, a broadly representative group of senior clinicians made substantial progress with the implementation of the new consultant contract, or at least with the sensitive issues arising from the diaries we are now urged to keep to define our workloads.

The orthopod who had addressed the haggis was sceptical. He thought a 40-hour week divided into 30-minute slots and 24 possible categories of work simply did not take account of day to day reality in Auchendreich. His average week was 60 hours at least, and at 7 30 that morning he had been at his desk dictating operation notes, viewing x rays, reviewing a registrar audit proposal, and teaching three students—all while awaiting a response from the still problematical switchboard of our flagship new PFI hospital.

Other surgeons nodded in support, and a pleasant new consultant psychotherapist—whose response to the toast “the lassies” had astonished the company both by its length and its emphatic feminism—agreed strongly. If she did not spend at least half an hour reflecting on the previous hour's interaction, then both patient and therapist would have wasted their time.

A forceful and garrulous paediatrician proposed to claim extra sessions for her routine 45-minute meetings with parents, then was badly let down by a terse colleague who pointed out that 15 or even 10 minutes was usually plenty, provided you remembered to let the parents talk too. But by the time the final round of single malts appeared there was broad agreement: even if we worked in different ways, we all worked hard and should all be paid far better for it. Fittingly, the last word came from Burns, as quoted by the chaplain afterwards, though quietly and between ourselves in the car park: “O would some power the giftie gie us, to see ourselves as others see us.”
FRI0053 Correlation Between Substance P Serum Levels and Disease Activity in Rheumatoid Arthritis
Authors: R.E. Barbosa-Cobos, L.T. Becerril-Mendoza, G. Lugo-Zamudio, P. Rodríguez-Henríquez, J.J. Flores-Estrada, R. Monter-Vera, H.I. Rocha-González, R.I. Castillo-Castañeda, M.N. Medina-Pastor, J.D. Toscano-Garibay
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Substance P (SP) is a neuropeptide involved in the neurogenic inflammation of rheumatoid arthritis (RA) and is increased in serum and synovial fluid of patients with the disease. <h3>Objectives</h3> To evaluate the possible correlation between SP serum levels and RA activity assessed by disease activity score (DAS) 28 joints-C reactive protein (CRP) and German 7-Joint Ultrasound Score (GUS7). <h3>Methods</h3> Ninety RA patients (32 in remission, 8 with low disease activity, 42 with moderate disease activity and 8 with high disease activity assessed by DAS28-PCR) and 24 healthy controls were included. GUS7 was performed by evaluating synovitis and synovial/tenosynovial vascularity semiquantitatively (grade 0–3) by gray-scale (GS) and power Doppler (PD) ultrasound using an 18-mHz linear transducer. SP serum levels were measured by enzyme-linked immunosorbent assay. Correlation was estimated by Spearman9s correlation coefficient. <h3>Results</h3> SP serum levels were statistically different between controls and patients in remission or with different grades of disease activity (P≤0.05). Furthermore, positive tendency between SP serum levels and RA activity was observed. SP showed significant correlation with DAS28-CRP, tender joint count, swollen joint count and visual analog scale (VAS) by Spearman9s correlation coefficient. No correlation was found between SP and CRP or GUS7. <h3>Conclusions</h3> SP appears to be a potential RA activity biomarker. Notwithstanding, it is unlikely that SP itself provides sufficient discrimination in regard to rheumatoid arthritis activity given the complexity and heterogeneous etiology of this disease. In this regard, further studies of SP as a biological marker are necessary for its inclusion in a multi-biomarker equation that considers the neurogenic pathway participation in the pathogenesis of RA. <h3>References</h3> O9Connor TM, O9Connell J, O9Brien DI, Goode T, Bredin CP, Shanahan F. The Role of Substance P in Inflammatory Disease. J Cell Physiol 2004; 201:167-180. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32:31-35. Grimsholm O, Rantapää-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R416-R426. Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, et al. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol 2011; 21:244–250. <h3>Disclosure of Interest</h3> None declared
Controversy over psychiatric tourism
Authors: A. M Parshall
Journal: BMJ (1995)

A real phenomenon…

EDITOR,--I run a community psychiatric service adjacent to that of Charles Tannock in the west end of London.1 It is particularly closely integrated with social services and fully observes the principles of care management and the care programme approach.

I suspect that psychiatric tourism is well known. I have repeatedly presented audits showing that the phenomenon has an impact on our inpatient service. The data show that about half of the patients admitted are homeless (people staying in hostels are counted …
AB1121 Anti-TNF Drugs May Result to Elevated Abortion Rates in Late Pregnancy
Authors: G. Kimyon, O. Zengin, B. Kısacık, A.M. Onat
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatic diseases are prevalent especially in the fertile ages for women. Biologic DMARDs (disease modifying anti-rheumatic drugs) are commonly used in the treatment of these patients and there is a growing concern while safety data in pregnancy is insufficient. <h3>Objectives</h3> We herein documented our anti-TNF (tumor necrosis factor) drugs data whom using/used biologic drugs; adalimumab (ADA), infliximab (INF), etanercept (ETA), golimumab (GOL) and others in their pregnancy. <h3>Methods</h3> 653 women with a history of biologic DMARD exposure were included (until December 2014) and 47 conception were documented form the medical files. 4 of patients whom couldn9t be reached due to loss of follow up were excluded. Abortion was classified depending to patient9s statements and medical reports. Age, pregnancy age, abortion with and before biologics, complications, disease activity, smoking, HAQ score, drug exposure were analyzed. Patients with secondary causes for miscarriage were also excluded. <h3>Results</h3> Mean (33.3±10.3) and pregnancy age (31.9±9.9), disease distribution (22 AS, 14 RA, 5 PsA, 1 Behçet9s disease, 1 Takayasu), drug exposure (20 ADA, 13 INF, 7 ETA, 3 GOL) was found and 7 miscarriages in 7 of the patients (5 AS, 2 RA) and 1 premature birth were detected. Mean abortion time was 7.2±3.2 weeks. 3 patients ADA, 2 patients INF, 1 patient ETA and 1 patient GOL usage was defined. Mean abortion age was 35.3±7.7 and that was higher than the other patients but there was not statistical significance. Disease activity, HAQ scores, smoking was not different between two groups. <h3>Conclusions</h3> Anti-TNF drugs are well tolerated during pregnancy. However the wonder for the safety still exists. Elevated abortion rate in the late pregnancy with these drugs are remarkable. The discrepancy for each drug and its9 own risk could not be demonstrated due to a need with higher patient numbers. <h3>References</h3> Ostensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy?. Curr Opin Pharmacol. 2013 Jun;13(3):470-5. Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):607-11. <h3>Disclosure of Interest</h3> None declared
Case 12-1974
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Christopher Longcope, Robert E. Scully
Journal: New England Journal of Medicine (1974)

Presentation or Case First admission. A 35-year-old nurse, para 2, gravida 4, was admitted to the hospital because of obesity and hirsutism of six years' duration.Six years before entry, after an uncomplicated fullterm delivery, the patient gained 31 kg in weight over a period of six weeks. During that time she began to lose hair in the temporal areas, with the appearance of hair on the face, chest and lower portion of the abdomen and the development of acne on the face and shoulders. Her voice became somewhat hoarse. In the next two years she gained an additional . . .
The Excretion of Radioactivity during a Four-Day Period Following the Feeding of Carbon 14-Labeled 2-Acetylaminofluorene to Rats&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: John H. Weisburger, Elizabeth K. Weisburger, Harold P. Morris
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article The Excretion of Radioactivity during a Four-Day Period Following the Feeding of Carbon 14-Labeled 2-Acetylaminofluorene to Rats Get access John H. Weisburger, John H. Weisburger Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth K. Weisburger, Elizabeth K. Weisburger Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold P. Morris Harold P. Morris National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 4, February 1951, Pages 797–803, https://doi.org/10.1093/jnci/11.4.797 Published: 01 February 1951 Article history Received: 17 October 1950 Published: 01 February 1951
Psychotherapy for depression
Authors: Yutaka Ono
Journal: American Journal of Psychiatry (1990)

Research on the treatment of depression has shown that both pharmacological and psychosocial interventions are equally efficacious in mild depression as well as moderate and severe depression. Combined psychosocial and pharmacological interventions are also thought to be effective even for severe and chronic depression. Among psychosocial treatments, cognitive behavior therapy, behavior therapy, and interpersonal psychotherapy have been proved to effective. Cognitive behavior therapy is a structured short-term therapy designed to change the patient's negatively distorted cognition. Behavior therapy is a therapy developed based on the understanding that depression is related to a decrease of behaviors that produce positive reinforcement. Interpersonal psychotherapy is a form of short-term therapy to focus on the patient's interpersonal relations with significant others.